The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

DICP, The Annals of Pharmacotherapy: Vol. 24, No. 12, pp. 1214-1219.
© 1990 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sobotka, J.
Right arrow Articles by Cook, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sobotka, J.
Right arrow Articles by Cook, B.

Research Articles

A review of carbamazepine's hematologic reactions and monitoring recommendations

JL Sobotka, B Alexander, and BL Cook

Early case reports of fatal hematologic effects attributed to carbamazepine (CBZ) resulted in extensive monitoring recommendations by the manufacturer. The rarity of blood dyscrasias led many authors to question the manufacturer's guidelines. Thus the manufacturer removed specific monitoring guidelines, allowing physicians to monitor CBZ using their clinical judgment. This article reviews case reports and studies of CBZ's hematologic effects. Due to their rapid onset, daily laboratory checks would be necessary to monitor for aplastic anemia, agranulocytosis, and thrombocytopenia. These adverse effects are best monitored by informing patients and physicians to carefully watch for signs and symptoms. Leukopenia develops more slowly, occurring in approximately 12 percent of children and 7 percent of adults. Its onset is typically within the first three months of treatment, with patients at risk having a low or low-normal pretreatment white blood cell (WBC) count. Leukopenia often reverses, even if CBZ is continued. Based upon our review of the literature, we recommend monitoring of those high-risk patients during the first three months of treatment with the frequency being determined by results of each laboratory value. WBC counts less than 3000/mm3 or neutrophil counts below 1000/mm3 warrant a decrease in dose with frequent monitoring or CBZ discontinuation, if necessary.


This article has been cited by other articles:


Home page
 Mayo Clin Proc.Home page
H. Chen, T. J. Lamer, R. H. Rho, K. A. Marshall, B. T. Sitzman, S. M. Ghazi, and R. P. Brewer
Contemporary Management of Neuropathic Pain for the Primary Care Physician
Mayo Clin. Proc., December 1, 2004; 79(12): 1533 - 1545.
[Abstract] [PDF]

Home page
 The PsychiatristHome page
D. Nelson and D. A. Gray
Anticonvulsant monitoring in psychiatric practice
The Psychiatrist, September 1, 2001; 25(9): 356 - 358.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
M. Gardner, L. Ditmanson, R. W Garrett, T. Luu, and F. Meiling
Anticonvulsant Use in Treating Dementia-Related Agitation
Journal of Pharmacy Practice, August 1, 2000; 13(4): 308 - 315.
[Abstract] [PDF]

Home page
 NeurologyHome page
C. Willert, S. Englisch, S. Schlesinger, and U. Runge
Possible drug-induced thrombocytopenia secondary to tiagabine
Neurology, March 1, 1999; 52(4): 889 - 889.
[Full Text] [PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 1990 by Harvey Whitney Books Company.